Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eloxx Pharmaceuticals (ELOX) reported third-quarter financial results and progress in its exaluren clinical programs for rare kidney diseases. Net loss widened to $5.543 million from $0.351 million a year earlier, while loss per share narrowed to $0.49 from $0.58. Cash and cash equivalents were $56.264 million at September 30, 2026; Eloxx expects funding to last into 2028.
The first two patients received treatment in the Phase 2b EXACT Alport syndrome trial. Eloxx expects 16-week topline results in mid-2027 and final 32-week data by year-end 2027. The Phase 2 EXPRESS protocol for nonsense mutation ADPKD was finalized, and FDA clearance permits U.S. clinical sites to open. Eloxx expects first dosing in the third quarter of 2027 and 52-week topline results in the first half of 2029. In October, T.R. Srinivas became chief medical officer and Geno Germano joined the board.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointPhase 2b EXACT dosed its first two patients; planned enrollment is 24 patients with nonsense mutation Alport syndrome.
- Moderate pointEXPRESS received FDA IND clearance on October 29, 2026, enabling U.S. clinical sites to open.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Eloxx expects its cash and cash equivalents to fund operations into 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.EXACT results are expected in mid-2027 for 16-week data and by year-end 2027 for final 32-week data.
- Minor pointEarlier open-label Phase 2a biopsies showed structural improvements in all three participants.
6 minor points
- Minor pointEXPRESS protocol was finalized for approximately 60 adults, randomized 1:1 to exaluren or placebo for 52 weeks.
- Minor point. Forward-looking: it has not happened yet and may not happen.EXPRESS first dosing is expected in third-quarter 2027, with 52-week topline results in first-half 2029.
- Minor pointThird-quarter other income, net, reached $410,000, versus $66,000 in other expense a year earlier.
- Minor pointNine-month other income, net, was $400,000, versus $862,000 in other expense a year earlier.
- Minor pointTotal assets reached $58.261 million at September 30, 2026, versus $5.270 million at December 31, 2025.
- Minor pointStockholders' equity reached $41.069 million, versus an $11.907 million deficit at December 31, 2025.
Negative
- Moderate pointThird-quarter net loss widened to $5.543 million from $351,000; loss per share narrowed to $0.49 from $0.58.
- Moderate pointThird-quarter R&D expense rose to $4.028 million from a $250,000 credit a year earlier.
- Moderate pointCash and cash equivalents declined from $62.0 million at June 30 to $56.264 million at September 30, 2026.
- Minor pointNine-month net loss widened to $13.799 million from $3.951 million; loss per share narrowed to $1.83 from $9.12.
- Minor pointThird-quarter administrative expense rose to $1.925 million from $535,000 a year earlier.
3 minor points
- Minor pointNine-month R&D expense increased to $8.528 million from $1.158 million a year earlier.
- Minor pointNine-month administrative expense increased to $5.671 million from $1.931 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential EXPRESS Breakthrough Therapy Designation depends on clinical results and further FDA review.
News Explained
In
Key Figures
- Quarterly net loss
- $5.5 million vs. $0.4 million
- Three months ended September 30, 2026 vs. the same period in 2025
- Nine-month net loss
- $13.8 million vs. $4.0 million
- Nine months ended September 30, 2026 vs. the same period in 2025
- Cash and cash equivalents
- $56.3 million
- As of September 30, 2026; compared with $62.0 million as of June 30, 2026
- Cash runway
- Into 2028
- Company estimate for funding operations
- EXACT study enrollment
- 24 patients
- Phase 2b study in nonsense mutation Alport syndrome
- EXACT topline data
- Mid-2027
- Expected from the 16-week placebo-controlled portion
- EXPRESS study enrollment
- Approximately 60 adults
- Planned Phase 2 study in nonsense mutation ADPKD
- EXPRESS first patient dosing
- Third quarter of 2027
- Expected timing
Previous Earnings Reports
-
Public offering strengthened cash position and extended runway; quarterly net loss increased year over year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adpkd medical
nonsense mutations medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027
- Finalized protocol and received IND clearance for Phase 2 EXPRESS study of exaluren in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD); first patient expected to be dosed in the third quarter of 2027
- Expanded leadership team with appointment of T.R. Srinivas, M.D., as SVP, Chief Medical Officer
- Cash and cash equivalents of
as of September 30, 2026$56.3 million
"The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
Recent Business Highlights
- Phase 2b EXACT study in nonsense mutation Alport syndrome (NMAS)
- In September 2026, the Company announced that the first two patients had been dosed in its Phase 2b EXACT study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial of exaluren designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes. The primary efficacy endpoint of the initial 16-week placebo-controlled portion of the trial is the change in podocyte foot process effacement, measured as the change in filtration slit density on kidney biopsies, in non-
U.S . pediatric patients and all adult patients. - An earlier open-label Phase 2a study observed structural improvements, including reduced foot process effacement and improved GBM width, in kidney biopsies in all three participants.
- The Company expects to report topline data from the 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027.
- In September 2026, the Company announced that the first two patients had been dosed in its Phase 2b EXACT study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial of exaluren designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes. The primary efficacy endpoint of the initial 16-week placebo-controlled portion of the trial is the change in podocyte foot process effacement, measured as the change in filtration slit density on kidney biopsies, in non-
- Phase 2 EXPRESS study in nonsense mutation ADPKD (nmADPKD)
- The Company finalized the design of the 52-week EXPRESS study. EXPRESS is designed as a global, randomized, placebo-controlled trial in approximately 60 adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes, who will be randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), as measured by magnetic resonance imaging. Eloxx estimates that 40,000 to 50,000 people in
the United States have ADPKD caused by nonsense mutations. - On October 29, 2026, the Company announced FDA clearance of the IND for exaluren in nmADPKD, enabling it to open
U.S . clinical sites. - The Company expects to dose the first patient in the third quarter of 2027 and to report 52-week topline data in the first half of 2029. In pre-IND feedback reported by Eloxx in October, FDA indicated that a substantial and durable effect on kidney volume growth, with supporting kidney function and safety data, could be a potential basis for Breakthrough Therapy Designation. Any designation would depend on the clinical results and further FDA review.
- The Company finalized the design of the 52-week EXPRESS study. EXPRESS is designed as a global, randomized, placebo-controlled trial in approximately 60 adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes, who will be randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), as measured by magnetic resonance imaging. Eloxx estimates that 40,000 to 50,000 people in
- Expanded leadership team and Board of Directors
- In October 2026, the Company appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer, responsible for leading its renal medical strategy across its Alport syndrome and ADPKD programs. Dr. Srinivas joined Eloxx from Novartis, where he held
U.S . Medical Affairs leadership responsibilities for ADPKD product development. - Also in October 2026, the Company's Board of Directors appointed Geno Germano as a director, effective October 19, 2026. Mr. Germano brings more than 35 years of biopharmaceutical development and commercialization leadership. He most recently served as President and Chief Executive Officer of Elucida Oncology, and previously served as President of Intrexon (now Precigen) and as Group President of Pfizer's Global Innovative Pharmaceutical business. He currently serves as Chairman of Entera Bio and as a director of Precision BioSciences and Harmony Biosciences and has previously served on the boards of Sage Therapeutics, Bioverativ, The Medicines Company and Zoetis.
- In October 2026, the Company appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer, responsible for leading its renal medical strategy across its Alport syndrome and ADPKD programs. Dr. Srinivas joined Eloxx from Novartis, where he held
Third Quarter 2026 Financial Results
In May 2026, the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000. All share and per-share amounts in this press release reflect the reverse stock split.
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Other income, net was
Net loss for the three months ended September 30, 2026, was
Cash position. As of September 30, 2026, the Company had cash and cash equivalents of
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
For more information, please visit www.eloxxpharma.com. The corporate presentation and investor event information are available at www.eloxxpharma.com/investors/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including, without limitation, statements regarding the sufficiency of the Company's cash and cash equivalents to fund its operations; the expected timing of enrollment in, and topline and final data from, the Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; the expected timing of initiation of, and topline data from, the planned Phase 2 EXPRESS study of exaluren in nonsense mutation ADPKD; the potential for exaluren to receive Breakthrough Therapy Designation or to be eligible for accelerated approval or other expedited regulatory pathways; the potential benefits of orphan drug designation; the Company's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; the Company's collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company's product candidates to treat diseases caused by nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as "aim," "may," "will," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "potential," "seeks," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company's need for and ability to obtain additional capital; the uncertainty of timing, results and expense related to the clinical and regulatory development process; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and elsewhere in the Company's filings with the SEC, accessible on the SEC's website at www.sec.gov and on the "Financials & Filings" page of the Company's website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.
Contact
Investor Relations
Eloxx Pharmaceuticals, Inc.
ir@eloxxpharma.com
(781) 577-5300
|
ELOXX PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) |
||||||||||||
|
|
||||||||||||
|
|
Three Months Ended |
Nine Months Ended |
||||||||||
|
|
September 30, |
September 30, |
||||||||||
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
$ |
4,028 |
|
$ |
(250) |
|
$ |
8,528 |
|
$ |
1,158 |
|
|
General and administrative |
|
1,925 |
|
|
535 |
|
|
5,671 |
|
|
1,931 |
|
|
Total operating expenses |
|
5,953 |
|
|
285 |
|
|
14,199 |
|
|
3,089 |
|
|
Loss from operations |
|
(5,953) |
|
|
(285) |
|
|
(14,199) |
|
|
(3,089) |
|
|
Other (income) expense, net |
|
(410) |
|
|
66 |
|
|
(400) |
|
|
862 |
|
|
Net loss |
$ |
(5,543) |
|
$ |
(351) |
|
$ |
(13,799) |
|
$ |
(3,951) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted |
$ |
(0.49) |
|
$ |
(0.58) |
|
$ |
(1.83) |
|
$ |
(9.12) |
|
|
Weighted average number of shares of common stock |
|
11,404,791 |
|
|
604,278 |
|
|
7,551,283 |
|
|
433,358 |
|
|
ELOXX PHARMACEUTICALS, INC. Condensed Consolidated Balance Sheet Data (in thousands) (2026 unaudited) |
||||||
|
|
||||||
|
|
September 30, |
December 31, |
||||
|
|
2026 |
|
2025 |
|
||
|
Cash and cash equivalents |
$ |
56,264 |
|
$ |
4,785 |
|
|
Total assets |
$ |
58,261 |
|
$ |
5,270 |
|
|
Total current liabilities |
$ |
17,192 |
|
$ |
17,177 |
|
|
Total stockholders' equity (deficit) |
$ |
41,069 |
|
$ |
(11,907) |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update-302939970.html
SOURCE Eloxx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Eloxx expect results from the exaluren EXACT trial?
Eloxx expects topline results from EXACT's 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027. The Phase 2b trial has dosed its first two patients and is designed to enroll 24 patients with nonsense mutation Alport syndrome.
What does Eloxx's EXACT trial measure as its primary endpoint?
EXACT's initial 16-week primary efficacy endpoint measures changes in kidney filtration structures through kidney biopsies. Specifically, it assesses changes in podocyte foot process effacement using filtration slit density, in non-U.S. pediatric patients and all adult patients.
What is the primary endpoint of Eloxx's EXPRESS trial?
EXPRESS measures the annualized rate of change in height-adjusted total kidney volume using magnetic resonance imaging. The trial is designed for adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes.
What could support Breakthrough Therapy Designation for Eloxx's exaluren in ADPKD?
A substantial and durable effect on kidney volume growth, supported by kidney function and safety data, could potentially support Breakthrough Therapy Designation. Eloxx reported this FDA feedback from pre-IND discussions; any designation would depend on clinical results and further FDA review.
Why did Eloxx's third-quarter 2026 research expenses increase?
Eloxx attributed the increase primarily to higher clinical trial expenses associated with starting Phase 2b EXACT and increased personnel costs. The year-earlier comparison also benefited from a $0.9 million write-off of vendor accounts payable balances under settlement agreements.